STRATA Skin Sciences (SSKN) announces that the American Medical Association, AMA, CPT Editorial Panel, in its May, 2025 summary of panel actions has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA’s XTRAC Excimer Lasers, a safe, effective, non-drug treatment for patients with chronic inflammatory and autoimmune skin diseases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- STRATA Skin Sciences’ Earnings Call Highlights Growth Amid Challenges
- STRATA Skin Sciences Reports Q1 2025 Financial Results
- Strata Skin Sciences Reports Q1 2025 Financial Results
- Strata Skin Sciences price target lowered to $14 from $16 at Ladenburg
- Strata Skin Sciences Reports Positive Earnings with Key Growth Areas
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue